Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia.
Saved in:
| Title: | Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia. |
|---|---|
| Authors: | Woźniak, Ewelina1 (AUTHOR) ewelina.wozniak@umed.lodz.pl, Woźniak, Agnieszka1,2 (AUTHOR), Pawlos, Agnieszka1 (AUTHOR), Broncel, Marlena1,2 (AUTHOR), Satała, Joanna1 (AUTHOR), Bukowska, Bożena2 (AUTHOR), Gorzelak-Pabiś, Paulina1 (AUTHOR) |
| Source: | International Journal of Molecular Sciences. Nov2025, Vol. 26 Issue 21, p10529. 14p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
